SIRPA and metabolic dysfunction-associated steatotic liver disease: Thus, our current model and its formulation can instead serve as a high-quality mechanistic computational platform that can be accordingly and continuously expanded and enriched with additional pathway details to further investigate macrophage functions in specific disease areas of interest, e.g., TLR pathways in various infectious disease settings (O'neill et al., 2009), CD47/SIRPα axis in macrophage-mediated cancer immunotherapy (Weiskopf, 2017), and cellular metabolic pathways in nonalcoholic fatty liver disease (Oates et al., 2019).